Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

MD Anderson Cancer Center and Pfizer Oncology Announce Clinical Collaboration to Evaluate Immuno-Oncology Combinations in Blood Cancers and Solid Tumors

(MD Anderson) Sept 26, 2017 - The University of Texas MD Anderson Cancer Center and Pfizer Inc. today announced that they have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies.

read press release

Nation’s Experts in Hematologic Malignancies to Discuss Latest Treatment Advances and Examine Patient Cases during NCCN 12th Annual Congress

(NCCN) Sept 22, 2017 - NCCN 12th Annual Congress: Hematologic Malignancies™ will be held October 6 – 7, 2017 in San Francisco, California, and features a new Nursing Forum.

read press release

Novartis's $475,000 Price Tag on Cancer Drug Meets Resistance

(Bloomberg) Sept 22, 2017 - The $475,000 price tag on Novartis AG’s latest breakthrough cancer therapy came under fire from one of the biggest managers of drug costs in the U.S., underscoring the challenges the Swiss drugmaker will face in promoting the potential blockbuster.

read article

Viewpoint: FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug

(The JAMA Network) Sept 20, 2017 - The science underlying chimeric antigen receptor T cells (CAR-T) heralds a new era of treatment, and the list price of $475 000 for the new drug tisagenlecleucel (Kymriah; Novartis) (delivered as a one-time infusion) definitively shattered oncology drug pricing norms.

read article

Study Shows Diet And Exercise Improve Treatment Outcomes For Obese Pediatric Cancer Patients

(MD Anderson) Sept 21, 2017 - Diet and exercise may improve treatment outcomes in pediatric cancer patients, according to a study at The University of Texas MD Anderson Cancer Center.

read press release

Featured Research From 2017 Palliative and Supportive Care in Oncology Symposium Explores Communication, Quality of Life Issues for People With Cancer

(ASCO) Sept 20, 2017 - New research examining patient-physician communication, yoga as supportive care, and psychosocial support for people with cancer will be featured in the official Press Program for the 2017 Palliative and Supportive Care in Oncology Symposium.

read press release

Novartis's Rydapt Wins EU Approval For AML, Other Diseases

(Reuters) Sept 20, 2017 - Swiss drugmaker Novartis on Wednesday said it had won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals it secured in April.

read article

AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

(AbbVie) Sept 18, 2017 - Results of a multicenter, open-label, randomized Phase 3 study of VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in combination with Rituxan® met the primary endpoint of prolonged progression-free survival compared with bendamustine in combination with Rituxan in patients with relapsed/refractory CLL

read corporate press release

Imatinib a Double-Edged Sword for Patients With CML Who Become Pregnant

(Medscape Medical News) Sept 19, 2017 - Women who are taking imatinib (Gleevec, Novartis) for the treatment of chronic myeloid leukemia (CML) are at high risk for fetal congenital malformation if they become pregnant and should be counseled to terminate the pregnancy if it is unplanned, a retrospective analysis suggests.

read article (free registration required)

Caring At Home For A Child With Cancer Can Leave Family Members With Risky Tasks

(Washington Post) Sept 16, 2017 - Complex care is needed to prevent infection. Many parents don’t know how to provide it.

read article (free registration required)

Autolus Announces Initiation of the AMELIA and ALEXANDER Studies for AUTO3: Phase I/II Studies in Paediatric ALL and DLBCL

(Autolus) Sept 18, 2017 - Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced initiation of both the AMELIA and ALEXANDER phase I/II studies of its novel, dual-targeting, AUTO3 Chimeric Antigen Receptor (CAR) T-cell therapy.

read corporate press release

Antibiotic Identified That Reduces Infection Risk In Young Leukemia Patients

(St. Jude Children’s) Sept 14, 2017 - St. Jude Children's Research Hospital investigators report preventive antibiotic therapy, particularly with levofloxacin, reduced the odds of infections in at-risk pediatric leukemia patients early in cancer treatment.

read press release

Perspective: Tragedy, Perseverance, and Chance — The Story of CAR-T Therapy

(NEJM.org) Sept 13, 2017 - Though the remissions achieved with CAR-T therapy are impressive, much remains unknown. CAR-T products vary in ways that will have implications for both efficacy and toxicity. Meanwhile, the CAR-T discussion has become dominated by cost concerns.

read article

MD Anderson And Daiichi Sankyo Enter Research Collaboration To Accelerate Development Of Acute Myeloid Leukemia Therapies

(MD Anderson) Sept 14, 2017 - The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML).

read press release

Powerful Childhood Cancer Treatment Holds Promise--and Poses Hazards

(Scientific American) Sept 12, 2017 - Researchers say harsh side effects and puzzling gaps in effectiveness can be tweaked.

read article

Teva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

(Yahoo! Finance) Sept 12, 2017 - Teva Pharmaceutical Industries Ltd. announced today the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental New Drug Application (sNDA) for the use of TRISENOX® (arsenic trioxide) injection in combination with all-trans retinoic acid (ATRA) for induction of remission and consolidation in patients with newly diagnosed low or intermediate risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

read article

New Gene-Therapy Treatments Will Carry Whopping Price Tags

(New York Times) Sept 11, 2017 - Kymriah, approved recently by the F.D.A., with a $475,000 price tag, is first of a coming wave of treatments whose expected prices have alarmed economists, scientists and insurers.

read article

Roche Under Pressure As Second Rituximab Biosimilar Filed in US

(pharmaphorum [UK]) Sept 12, 2017 - The pressure is mounting on Roche after Swiss rival Sandoz filed a US biosimilar of cancer and inflammatory diseases drug rituximab, closely behind a rival from Teva and Celltrion.

read article

Novartis Says Biosimilar Rituximab Accepted For Review By FDA

(Reuters) Sept 12, 2017 - Novartis AG said on Tuesday its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. Food and Drug Administration (FDA).

read article

Insight into How Lungs Repel Infection Could Guide Therapies for Transplant Patients

(MSK/On Cancer Blog) Sept 7, 2017 - Learn how immune cells in the lungs trigger invasive fungal cells to self-destruct. The discovery could produce therapies to prevent infection in cancer patients.

read article
Next Page